Skip to main content
. 2004 Jan;16(1):157–171. doi: 10.1105/tpc.017889

Figure 1.

Figure 1.

VirD2 Is a Target for Human caspase-3.

(A) Fragmentation of the full-length VirD2 protein. Recombinant full-length VirD2 (lane 1) was treated with caspase-3 in the absence (lane 2) or in the presence (lane 3) of Ac-DEVD-CHO inhibitor. The reaction mixtures were analyzed by 10% SDS-PAGE directly (lanes 1 to 3) or after fractionation by Ni-NTA agarose chromatography (lanes 4 and 5), followed by Coomassie blue staining.

(B) caspase-3 cleavage sites are located within the C-terminal portion of VirD2. GFP-VirD2Ct (lane 1) was treated with caspase-3 in the absence (lane 2) or in the presence (lane 3) of Ac-DEVD-CHO inhibitor. The reaction mixtures were analyzed by 12% SDS-PAGE.

Thick and thin arrows point to the major and minor caspase cleavage products, respectively. The positions of the molecular mass markers are indicated at left.